PURPOSE: We performed a case-control study to evaluate the association of genetic polymorphisms of estrogen-metabolizing enzyme genes and estrogen receptor genes with breast cancer risk according to age group and subtypes in Korean women. METHODS: Breast cancer patients (n = 830) and the hospital healthy controls (n = 390) with both clinical information and SNP data were included in the study. Age was divided into three groups: premenopausal under 35 years (n = 64), premenopausal over 35 years (n = 456), and postmenopausal women (n = 310), respectively. Tumor subtype was classified into four subtypes: luminal A, luminal B, HER2-overexpressing, and triple-negative, respectively. Genotyping of the selected SNPs in ESR1, ESR2, CYP1A1, CYP1B1, and COMT was conducted using the VeraCode Golden Gate Genotyping Assay Technology. Multiple logistic regression models (dominant, recessive, and additive) were applied to determine the odds ratio, 95% confidence interval, and p value. RESULTS: ESR1, rs2881766, rs2077647, rs926778, and rs2273206 polymorphisms increased breast cancer risk, and rs3798377 decreased the risk in overall patients. The association between SNP genotype and breast cancer risk was varied according to age groups and tumor subtypes. For age subgroups, rs2881766 increased breast cancer risk in the all three age groups, and rs926778 increased the risk in premenopausal over 35 years women and in postmenopausal women. For the tumor subtypes, rs2881766 increased breast cancer risk manly in luminal A, HER2-overexpressing, and triple-negative subtypes except for luminal B subtype, and rs926778 increased the risk in luminal A and triple-negative subtypes. Rs3798577 decreased the risk in luminal B and triple-negative subtypes. CONCLUSION: The results showed that ESR1 rs2881766 polymorphism increased breast cancer risk and rs3798377 decreased the risk in Korean women. Because of wide variation of the association between SNP genotype and breast cancer risk according to age group and tumor subtypes, further studies such as a large-scale cohort study need for validation and test of biologic significance.
PURPOSE: We performed a case-control study to evaluate the association of genetic polymorphisms of estrogen-metabolizing enzyme genes and estrogen receptor genes with breast cancer risk according to age group and subtypes in Korean women. METHODS:Breast cancerpatients (n = 830) and the hospital healthy controls (n = 390) with both clinical information and SNP data were included in the study. Age was divided into three groups: premenopausal under 35 years (n = 64), premenopausal over 35 years (n = 456), and postmenopausal women (n = 310), respectively. Tumor subtype was classified into four subtypes: luminal A, luminal B, HER2-overexpressing, and triple-negative, respectively. Genotyping of the selected SNPs in ESR1, ESR2, CYP1A1, CYP1B1, and COMT was conducted using the VeraCode Golden Gate Genotyping Assay Technology. Multiple logistic regression models (dominant, recessive, and additive) were applied to determine the odds ratio, 95% confidence interval, and p value. RESULTS:ESR1, rs2881766, rs2077647, rs926778, and rs2273206 polymorphisms increased breast cancer risk, and rs3798377 decreased the risk in overall patients. The association between SNP genotype and breast cancer risk was varied according to age groups and tumor subtypes. For age subgroups, rs2881766 increased breast cancer risk in the all three age groups, and rs926778 increased the risk in premenopausal over 35 years women and in postmenopausal women. For the tumor subtypes, rs2881766 increased breast cancer risk manly in luminal A, HER2-overexpressing, and triple-negative subtypes except for luminal B subtype, and rs926778 increased the risk in luminal A and triple-negative subtypes. Rs3798577 decreased the risk in luminal B and triple-negative subtypes. CONCLUSION: The results showed that ESR1rs2881766 polymorphism increased breast cancer risk and rs3798377 decreased the risk in Korean women. Because of wide variation of the association between SNP genotype and breast cancer risk according to age group and tumor subtypes, further studies such as a large-scale cohort study need for validation and test of biologic significance.
Authors: Timothy R Rebbeck; Andrea B Troxel; Amy H Walker; Saarene Panossian; Stephen Gallagher; Ekaterina G Shatalova; Rebecca Blanchard; Sandra Norman; Greta Bunin; Angela DeMichele; Michelle Berlin; Rita Schinnar; Jesse A Berlin; Brian L Strom Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-03 Impact factor: 4.254
Authors: D S Yim; S K Parkb; K Y Yoo; K S Yoon; H H Chung; H L Kang; S H Ahn; D Y Noh; K J Choe; I J Jang; S G Shin; P T Strickland; A Hirvonen; D Kang Journal: Pharmacogenetics Date: 2001-06
Authors: Asta Försti; Chunyan Zhao; Elisabeth Israelsson; Karin Dahlman-Wright; Jan-Ake Gustafsson; Kari Hemminki Journal: Breast Cancer Res Treat Date: 2003-06 Impact factor: 4.872
Authors: Rachel Schiff; Suleiman A Massarweh; Jiang Shou; Lavina Bharwani; Syed K Mohsin; C Kent Osborne Journal: Clin Cancer Res Date: 2004-01-01 Impact factor: 12.531
Authors: Aesun Shin; Daehee Kang; Hisahide Nishio; Myeong Jin Lee; Sue Kyung Park; Sook-Un Kim; Dong-Young Noh; Kuk-Jin Choe; Se-Hyun Ahn; Ari Hirvonen; Ju Han Kim; Keun-Young Yoo Journal: Breast Cancer Res Treat Date: 2003-07 Impact factor: 4.872
Authors: Heather Spencer Feigelson; David G Cox; Howard M Cann; Sholom Wacholder; Rudolf Kaaks; Brian E Henderson; Demetrius Albanes; David Altshuler; Goran Berglund; Franco Berrino; Sheila Bingham; Julie E Buring; Noel P Burtt; Eugenia E Calle; Stephen J Chanock; Francoise Clavel-Chapelon; Graham Colditz; W Ryan Diver; Matthew L Freedman; Christopher A Haiman; Susan E Hankinson; Richard B Hayes; Joel N Hirschhorn; David Hunter; Laurence N Kolonel; Peter Kraft; Loic LeMarchand; Jakob Linseisen; William Modi; Carmen Navarro; Petra H Peeters; Malcolm C Pike; Elio Riboli; V Wendy Setiawan; Daniel O Stram; Gilles Thomas; Michael J Thun; Anne Tjonneland; Dimitrios Trichopoulos Journal: Cancer Res Date: 2006-02-15 Impact factor: 12.701
Authors: Simon N Stacey; Andrei Manolescu; Patrick Sulem; Steinunn Thorlacius; Sigurjon A Gudjonsson; Gudbjörn F Jonsson; Margret Jakobsdottir; Jon T Bergthorsson; Julius Gudmundsson; Katja K Aben; Luc J Strobbe; Dorine W Swinkels; K C Anton van Engelenburg; Brian E Henderson; Laurence N Kolonel; Loic Le Marchand; Esther Millastre; Raquel Andres; Berta Saez; Julio Lambea; Javier Godino; Eduardo Polo; Alejandro Tres; Simone Picelli; Johanna Rantala; Sara Margolin; Thorvaldur Jonsson; Helgi Sigurdsson; Thora Jonsdottir; Jon Hrafnkelsson; Jakob Johannsson; Thorarinn Sveinsson; Gardar Myrdal; Hlynur Niels Grimsson; Steinunn G Sveinsdottir; Kristin Alexiusdottir; Jona Saemundsdottir; Asgeir Sigurdsson; Jelena Kostic; Larus Gudmundsson; Kristleifur Kristjansson; Gisli Masson; James D Fackenthal; Clement Adebamowo; Temidayo Ogundiran; Olufunmilayo I Olopade; Christopher A Haiman; Annika Lindblom; Jose I Mayordomo; Lambertus A Kiemeney; Jeffrey R Gulcher; Thorunn Rafnar; Unnur Thorsteinsdottir; Oskar T Johannsson; Augustine Kong; Kari Stefansson Journal: Nat Genet Date: 2008-04-27 Impact factor: 38.330